Our clients in biotech, venture capital and pharma use our insights to improve their drug development programs.
We provide expertise in clinical medicine, human genetics, statistical genetics, bioinformatics and epidemiology to our clients.
Most decision makers in the bio-pharmaceutical landscape want to know the human genetic evidence supporting a drug target prior to making an investment.
We generate evidence for our clients in biotech so that they can demonstrate to their investors the strength of the human genetic evidence supporting their drug development program.
Evidence from multiple sources demonstrates that drug development programs with evidence from human genetics are 2-4 more times likely to be successful.
VCs use our insights prior to making investments to increase their ROI.
Pharmaceutical companies have made large-scale investments to obtain human genetics insights.
We work with established and growing human genetics teams inside pharmaceutical companies to improve their pipelines, algorithms and clinical insights.